• 1
    Lee JAH. Melanoma and exposure to sunlight. Epidemiol Rev 1982; 4:110136.
  • 2
    Milton GW. The diagnosis of malignant melanoma. In: McCarthyWH, eds. Melanoma and Skin Cancer. Sydney: Government Printer, 1973; 163174.
  • 3
    Elder DE, Greene MH, Bondi EE, Clark WH Jr. Acquired melanocytic naevi and melanoma: The dysplastic naevus syndrome. In: AckermanAB, eds. Pathology of Malignant Melanoma. New York: Masson, 1981; 185215.
  • 4
    Clark WH Jr, Elder DE, Guerry D IV, Epstein MN, Greene MH, Van Horn M. A study of tumour progression: The precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984; 15:11471165.
  • 5
    Holman CDJ, Armstrong BK. Pigmentary traits, ethnic origin, benign nevi, and family history as risk factors for cutaneous malignant melanoma. J Natl Cancer Inst 1984; 72:257266.
  • 6
    Swerdlow AJ, English J, MacKie RM, O'Doherty CJ, Hunter JAA, Clark J. Benign naevi associated with high risk of melanoma. Lancet 1984; 2:168.
  • 7
    Green A, Maclennan R, Siskind V. Common acquired naevi and the risk of malignant melanoma. Int J Cancer 1985; 35:297300.
  • 8
    Reynolds P, Austin D, Thomas J. Familial and occupational risks associated with malignant melanoma of the skin. Am J Epidemiol 1982; 116:570.
  • 9
    Holman CDJ, Armstrong BK, Heenan PJ. A theory of the origin of human cutaneous malignant melanoma. J Natl Cancer Inst 1983; 71:651656.
  • 10
    Cooke KR, Spears GFS, Skegg DCG. Frequency of moles in a defined population. J Epidemiol Community Health 1985; 39:4852.
  • 11
    Clark WH Jr, Reimer RR, Greene M, Ainsworth AM, Mastrangelo MC. Origin of familial malignant melanomas from heritable lesions: “The B-K mole syndrome.” Arch Dermatol 1978; 114:732738.
  • 12
    Greene MH, Clark WH Jr, Tucker MA, Kraemer KH, Elder DE, Fraser MC. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 1985; 102:458465.
  • 13
    Greene MH, Goldin LR, Clark WH Jr et al. Familial cutaneous malignant melanoma: Autosomal dominant trait possibly linked to the Rh locus. Proc Natl Acad Sci USA 1983; 80:60716075.
  • 14
    Bale SJ, Chakravarti A, Greene MH. Cutaneous malignant melanoma and familial dysplastic naevi: Evidence for autosomal dominance and pleiotropy. Am J Hum Genet 1986; 38:188196.
  • 15
    Lynch HT, Fusaro RM, Kimberling WJ, Lynch JF, Danes BS. Familial atypical multiple mole-melanoma (FAMMM) syndrome: Segregation analysis. J Med Genet 1983; 20:342344.
  • 16
    Elder DE, Goldman LI, Goldman SC, Greene MH, Clark WH Jr. Dysplastic nevus syndrome: A phenotypic association of sporadic cutaneous melanoma. Cancer 1980; 46:17871794.
  • 17
    Crutcher WA, Sagebiel RW. Prevalence of dysplastic naevi in a community practice. Lancet 1984; 1:729.
  • 18
    Rhodes AR, Sober AJ, Mihm MC Jr, Fitzpatrick TB. Possible risk factors for primary cutaneous malignant melanoma. Clin Res 1980; 28:252A.
  • 19
    Simpson FO, Paulin JM, Phelan EL et al. Further surveys in Milton, 1978 and 1981: Blood pressure, height, weight and 24-hour excretion of sodium and potassium. NZ Med J 1982; 95:873876.
  • 20
    Cooke KR. Frequency of benign naevi in the general population. In: ElwoodJM, eds. Melanoma and Naevi Incidence, Interrelationships, and Implications. Basel: Karger, 1988; 826.
  • 21
    Elder DE, Kraemer KH, Greene MH, Clark WH Jr, Guerry D IV. The dysplastic naevus syndrome: Our definition. Am J Dermatopathol 1982; 4:455460.
  • 22
    Lilienfeld AM, Lilienfeld DE. Foundations of Epidemiology, ed. 2. New York: Oxford University Press, 1980; 336338.
  • 23
    Fleiss JL. Statistical methods for rates and proportions. New York: Wiley, 1973; 146147.
  • 24
    Kraemer KH, Greene MH, Tarone R, Elder DE, Clark WH Jr, Guerry D IV. Dysplastic naevi and cutaneous melanoma risk. Lancet 1983; 2:10761077.
  • 25
    Findlay FJ. Cancer Data 1984 Edition: New Registrations and Deaths 1980. Wellington: National Health Statistics Centre, 1984; 1521.
  • 26
    Taylor MR, Guerry D IV, Bondi EE et al. Lack of association between intraocular melanoma and cutaneous dysplastic naevi. Am J Opthalmol 1984; 98:478482.
  • 27
    Nordlund JJ, Kirkwood J, Forget BM et al. Demographic study of clinically atypical (dysplastic) nevi in patients with melanoma and comparison subjects. Cancer Res 1985; 45:18551861.
  • 28
    McCarthy WH, Coates AS. The dysplastic naevus syndrome: Identifying the at-risk patient. Pat Manag 1985; 14:4353.
  • 29
    Kraemer KH, Greene MH. Dysplastic nevus syndrome: Familial and sporadic precursors of cutaneous melanoma. Dermatol Clin 1985; 3:225237.
  • 30
    Elder DE. Personal communication, 1985.
  • 31
    Koran LM. The reliability of clinical trials, data and judgements. J Natl Cancer Inst 1975; 293:642646, 695–701.
  • 32
    Heenan PJ, Matz LR, Blackwell JB et al. Inter-observer variation between pathologists in the classification of cutaneous malignant melanoma in Western Australia. Hisiopathology 1984; 8:717729.
  • 33
    Nicholls EM. Development and elimination of pigmented moles, and the anatomical distribution of primary malignant melanoma. Cancer 1973; 32:191195.
  • 34
    MacKie RM. Multiple melanoma and atypical melanocytic naevi: Evidence of an activated and expanded melanocytic system. Br J Dermatol 1982; 107:621629.